Increasing Minority Participation in Cancer Clinical Trials 1

2011 Diversity Conference by Oregon Department of Transportation is licensed under CC by 2.0

2011 Diversity Conference by Oregon Department of Transportation is licensed under CC by 2.0

Failing to recruit a diverse population of patients for clinical trials can have a negative impact on drug research. Last year, Lilly CEO John Lechleiter pointed out in a Forbes editorial that “when clinical trials are skewed toward Caucasians, researchers can miss key interactions between the drug and genes.” It’s unfortunate to think that we may be missing opportunities to create more effective treatments due to these gaps in knowledge and understanding.

National Minority Health Month and National Minority Cancer Awareness Week, observed each year in April, were created to address the issues preventing minorities from having full access to healthcare options. Among the many health-related disparities that minorities face are fewer opportunities to learn about and enroll in clinical research studies. This disparity is most pronounced in the area of cancer.

More…